JZP458 – Recombinant Erwinia Asparaginase for Treatment of ALL / LBL Patients With Hypersensitivity to E. Coli-derived Asparaginase
Condition(s):Acute Lymphoblastic Leukemia; Lymphoblastic LymphomaLast Updated:August 3, 2021Approved for marketing
Hide Studies Not Open or Pending
Condition(s):Acute Lymphoblastic Leukemia; Lymphoblastic LymphomaLast Updated:August 3, 2021Approved for marketing
Condition(s):Acute Lymphoblastic LeukemiaLast Updated:May 22, 2014Completed
Condition(s):Hematologic MalignancyLast Updated:June 26, 2018Withdrawn
Condition(s):Acute Lymphoblastic LeukemiaLast Updated:September 30, 2009Unknown status
Condition(s):Acute Lymphoblastic LeukemiaLast Updated:March 18, 2024Recruiting
Condition(s):Acute Lymphoblastic LeukemiaLast Updated:March 15, 2024Completed
Condition(s):Relapsed Acute Lymphoblastic Leukemia; Allergy to PEG e.Coli Asparaginase; Allergy to Native e.Coli AsparaginaseLast Updated:February 19, 2019Terminated
Condition(s):Acute Lymphoid LeukemiaLast Updated:March 1, 2011Completed
Condition(s):LymphomaLast Updated:February 20, 2012Unknown status
Condition(s):NK/T Cell LymphomaLast Updated:November 5, 2020Withdrawn
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.